Strides Q1 FY27: Ex-US momentum lifts growth, while freight headwinds keep margins in check

Strides Pharma Science began FY27 with steady growth, even as supply-chain volatility remained a recurring theme. For the quarter ended June 30, 2026 (Q1 FY27), the company reported revenue of ₹12,654 million, up 13 percent year on year. Gross margin improved slightly to 60.9 percent, while EBITDA rose 5.4 percent to ₹2,298 million.

Profitability was shaped by two moving parts. Operating performance stayed resilient, but elevated freight and operating costs linked to geopolitical disruptions created pressure at the EBITDA line. Management quantified this incremental impact at about ₹131 million for the quarter. Reported profit after tax was higher at ₹1,655 million, supported by an exceptional gain from the divestment of the majority stake in Pivot Path, the company’s captive global capability centre. Operational PAT, excluding exceptional items, stood at ₹1,231 million with operational EPS of ₹13.4.

The quarter in numbers

The company’s gross margin profile remained robust, with management reiterating an expectation of gross margins staying in the 58 to 60 percent range. EBITDA margin came in at 18.2 percent, down 130 basis points year on year, but broadly in line with the previous quarter.

Management positioned the quarter as a validation of the diversification strategy built over the last few years, with Ex-US markets acting as the key growth engine.

Geography mix: Ex-US grows faster than the company

Strides’ revenue split continues to be led by two core engines: the US generics business and a broad Ex-US platform spanning regulated markets, growth markets and branded franchises.

The company reported US revenue of ₹6,282 million in Q1 FY27, compared to ₹6,036 million in Q1 FY26, reflecting 4 percent growth in rupee terms. In dollar terms, the US business was $68 million versus$71 million a year ago, underscoring the impact of currency movement and a steady but competitive environment.

Ex-US markets delivered sharper growth. Revenue rose 17 percent year on year to ₹5,875 million ($63 million), supported by broad-based performance across markets. Management called out stronger outcomes in front-end markets such as the UK and Nordics, helped by dependable supply and customer advocacy. Africa, led by the Brands business, was highlighted as another contributor.

A sequential dip in Ex-US dollar revenue compared to Q4 FY26 was explained as timing-related. Management said shipment delays linked to supply-chain disruptions affected dispatches in a few markets. The company expects this spillover business to be recovered over subsequent quarters.

Beyond these two categories, the presentation included an Access Market line item described as tactical business.

US outlook: H2 expected to be stronger, with multiple growth levers

The US franchise remains central to Strides’ medium-term aspiration. Management reiterated an ambition to build a North America business of about $375 million by FY28, despite near-term headwinds.

In Q1, the company launched two products and reported 72 commercialized products in the US portfolio. It also noted that it ranks among the top three players in 37 products, which collectively account for about 70 percent of its US revenue. This concentration in leadership positions is a stabilizer, though the quarter still reflected competitive pressures in certain recently launched products.

Controlled substances were again positioned as a long-term growth lever, but management acknowledged that revenue growth in this area is being impacted by slower quota allocation. On the call, management explained that quota allocations typically occur twice a year, around June and December, and depend on past sales history. It also indicated the June cycle response was awaited.

The company’s medium-term strategy includes investing in niche platforms such as controlled substances, nasal sprays, transdermal patches and films. A second nasal spray (controlled substance) was filed in May 2026. On the call, management stated the first nasal spray program is in advanced review stages and it expects an approval in the second half of FY27, potentially around Q3 or Q4, though timelines can shift.

There is also an operational hedge in the backdrop of broader US policy uncertainty. Management noted it has built a US manufacturing presence through its Chestnut Ridge facility, with nearly one-third of US revenues supplied from this site. It also said key growth platforms are being developed around this US manufacturing base.

Costs, cash flow, and leverage: discipline with a working-capital trade-off

The company reported incremental freight and operating costs of about ₹131 million due to geopolitical disruptions. This, combined with higher manufacturing costs, kept EBITDA margin lower year on year.

Balance-sheet trends remained supportive. Reported net debt at the end of June 2026 was ₹14,246 million, down ₹119 million during the quarter. Net debt to EBITDA stood at 1.52x.

Operating cash flow for Q1 FY27 was ₹1,087 million, with management reporting EBITDA-to-cash conversion of 47 percent. The cash-to-cash cycle stood at 123 days, with a year-on-year increase explained by higher inventory levels built to ensure supply continuity in a disrupted environment.

CARE Ratings upgraded the company’s long-term bank facilities rating to CARE A+ Stable, which management cited as reflecting consistency in financial performance.

A notable disclosure was the OneSource investment. The company stated its retained interest in OneSource was worth ₹3,100 million as of July 30, 2026, and clarified that this value is not adjusted in net debt computation.

Corporate actions and ESG updates

Strides reported that it unlocked ₹1,000 million of value through the divestment of its majority stake in Pivot Path, while retaining meaningful participation in its future growth. In the earnings call, management quantified the gain from this divestment at ₹742 million, contributing ₹534 million to reported PAT net of tax.

On sustainability, the company reported an improvement in its EcoVadis sustainability score to 68 out of 100, a 19-point improvement year on year.

What to watch from here

Strides’ Q1 FY27 performance showed a business that is growing through diversification rather than relying on a single geography. Ex-US markets are now a clear driver, with management explicitly stating an expectation that Ex-US should grow faster than the company average over the foreseeable future.

The US business remains the key swing factor for the FY28 aspiration. Management expects the first half of FY27 to be soft and has pointed to approvals and launches in H2 FY27 as the catalyst. Investors will likely track three items closely: the pace and quality of US launches, resolution and outcomes related to quota allocations for controlled substances, and any updates on the Bengaluru plant USFDA inspection response timeline.

Overall, the quarter reinforced two themes. First, Strides is managing profitability through portfolio quality and gross margin control, even with freight-driven cost volatility. Second, the company is leaning on a broader geographical engine, with Ex-US increasingly positioned as both a growth and earnings driver.